Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26985255
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Clin+Med+Res
2016 ; 8
(4
): 334-7
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet s Disease:
Eight Consecutive Cases
#MMPMID26985255
Tanida S
; Mizoshita T
; Nishie H
; Ozeki K
; Katano T
; Shimura T
; Kubota E
; Kataoka H
; Kamiya T
; Joh T
J Clin Med Res
2016[Apr]; 8
(4
): 334-7
PMID26985255
show ga
The long-term efficacy and safety of adalimumab (ADA) for the treatment of
intestinal Behcet's disease (BD) in the clinical setting have not been evaluated
previously. This retrospective study evaluated the 52-week efficacy of ADA in BD
patients. A total of eight patients who were refractory to conventional therapy
were given ADA (160/80/40 mg every other week). Marked improvement (MI) was
achieved by 10 weeks in five patients (62.5%), and by 52 weeks in six patients
(75%). In addition, complete remission was obtained in two patients (25%) at both
10 and 52 weeks. Improvement of global gastrointestinal (GI) symptoms to score 0
was observed in three patients (37.5%) at 10 weeks and four patients (50%) at 52
weeks. Moreover, improvement of endoscopic assessment to score 0 was also seen in
four patients (50%) at both 10 and 52 weeks. No adverse events were observed in
any patients during the 52 weeks. In conclusion, ADA offers an effective,
well-tolerated treatment for intestinal BD in patients who are refractory to
conventional therapy.